1 / 4Morgan Stanley on HDFC: The brokerage was 'overweight' on the stock and raised its target to Rs 2,900 from Rs 2,600 per share. Return on equity (RoE) and earnings per share (EPS) growth are poised to stage a multi-year recovery, the brokerage noted, adding that the recovery will be supported by structurally stronger positioning among non-bank lenders.
2 / 4HSBC on SpiceJet: The brokerage had a 'hold' rating on the stock but cut its target to Rs 115 per share from Rs 130 earlier. As per the brokerage, the company's Q2 results were worse than expected, however, 737Max returning to operations by March could benefit cost.
3 / 4HSBC on Sun Pharma: The brokerage maintained 'hold' on the stock with a target at Rs 425 per share. A potential settlement with the United States Department of Justice would remove a major overhang for generics, said the brokerage. It added that timing and outcome remain uncertain.
4 / 4HSBC on Mahindra CIE: The brokerage maintained 'buy' call on the stock but reduced its target to Rs 230 per share from Rs 300 earlier. End-market demand has declined steeply in recent months, the brokerage noted, adding that key segments are likely to recover in the near term.
